Table 1 Inclusion criteria
P (Participants) | Women with a diagnosis of polycystic ovary syndrome |
I (Intervention) | Omega-3 fatty acid with no limits on the type, dose, frequency and so on |
C (Comparisons) | Blanks, placebo, or western medicine |
O (Outcomes) | Primary: the change of homeostatic model assessment (HOMA) of insulin resistance, total cholesterol (TC), triglyceride (TG), adiponectin, adverse events |
Secondary: body mass index (BMI), fasting insulin, fasting glucose, low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), follicle stimulating hormone (FSH), luteotropic hormone (LH), total testosterone, sex hormone-binding globulin (SHBG) | |
S (Study type) | Randomized controlled trials (RCTs), which assess the effects of omega-3 fatty for the treatment of PCOS (with no limits on the manner by which randomization has been achieved, on blinding or on the language of publication) |